Acumen Pharmaceuticals has filed preliminary conditions for a $125 million initial public offering. The company is working on an Alzheimer’s disease treatment. Here’s a look at my stock analysis./n
Read MoreAcumen Pharmaceuticals Pursues $125 Million IPO (Pending:ABOS)
2021-07-01T07:01:21-04:00July 1st, 2021|
Related Posts
-
Viking CEO: We are very different from big cruise lines
May 1st, 2024 -
Viking prices IPO at $24 per share
May 1st, 2024 -
Indian digital payments firm discusses IPO plans
April 18th, 2024